Ophthalmologica
EURETINA – Original Paper
Retinal Nerve Fiber Layer Analysis with Scanning Laser Polarimetry and RTVue-OCT in Patients of Retinitis PigmentosaXue K. · Wang M. · Chen J. · Huang X. · Xu G.Department of Ophthalmology, The Eye Ear Nose and Throat Hospital, Fudan University, Shanghai, China
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: January 24, 2011
Accepted: February 02, 2012
Published online: October 12, 2012
Issue release date: December 2012
Number of Print Pages: 5
Number of Figures: 1
Number of Tables: 2
ISSN: 0030-3755 (Print)
eISSN: 1423-0267 (Online)
For additional information: https://www.karger.com/OPH
Abstract
Purpose: To measure the thickness of the retinal nerve fiber layer (RNFL) of patients with retinitis pigmentosa (RP) and that of normal controls by scanning laser polarimetry with enhanced corneal compensation (GDxECC) and RTVue-optical coherence tomography (OCT). Methods: Fifty-two eyes of 26 patients were included. All patients underwent complete ophthalmological examinations and testing with GDxECC. Twenty-eight of 52 eyes of RP patients underwent RTVue-OCT measurements. A group of 50 eyes of 25 normal subjects (controls) was also included. GDxECC measured RNFL thickness in the peripapillary area in all subjects as well as temporal-superior-nasal-inferior-temporal (TSNIT) parameters, including TSNIT means, superior and inferior region means, TSNIT standard deviation (SD), inter-eye symmetry and nerve fiber indicator (NFI). RTVue-OCT measured the mean, superior, inferior, temporal and nasal quadrant RNFL thickness. Result: In RP patients and controls, TSNIT means by GDxECC were, respectively, 65.00 ± 7.35 and 55.32 ± 5.20. Mean superior quadrant thicknesses were80.56 ± 10.93 and 69.54 ± 7.45. Mean inferior thicknesses were 80.58 ± 9.34 and 69.12 ± 7.78. SDs were 27.92 ± 5.21 and 28.23 ± 4.01. Inter-eye symmetries were 0.82 ± 0.17 and 0.87 ± 0.09. NFIs were 9.74 ± 8.73 and 16.81 ± 8.13. The differences between mean TSNIT, mean superior and mean inferior quadrant thicknesses and NFIs were statistically significant (p < 0.001). In RTVue-OCT measurements, the differences between mean, superior, inferior and temporal quadrant RNFL thicknesses were statistically significant (p = 0.0322, 0.0213, 0.0387, 0.0005). Conclusions: The RNFL measured by GDxECC was significantly thicker in RP patients than in controls. RNFL thickness measured by RTVue-OCT was significantly greater in RP patients than in controls in the superior, inferior and temporal regions. This contribution provides information on RNFL thickness and discusses the mechanism underlying this phenomenon.
© 2012 S. Karger AG, Basel
Related Articles:
References
- Szamier RB, Berson EL, Klein R, Meyers S: Sex-linked retinitis pigmentosa: ultrastructure of photoreceptors and pigment epithelium. Invest Ophthalmol Vis Sci 1979;18:145–160.
- Milam AH, Li ZY, Fariss RN: Histopathology of the human retina in retinitis pigmentosa. Prog Retin Eye Res 1998;17:175–205.
- Fariss RN, Li ZY, Milam AH: Abnormalities in rod photoreceptors, amacrine cells, and horizontal cells in human retinas with retinitis pigmentosa. Am J Ophthalmol 2000;129:215–223.
- Newman NM, Stevens RA, Heckenlively JR: Nerve fibre layer loss in diseases of the outer retinal layer. Br J Ophthalmol 1987;71:21–26.
- Stone JL, Barlow WE, Humayun MS, de Juan E Jr, Milam AH: Morphometric analysis of macular photoreceptors and ganglion cells in retinas with retinitis pigmentosa. Arch Ophthalmol 1992;110:1634–1639.
- Santos A, Humayun MS, de Juan E Jr, et al: Preservation of the inner retina in retinitis pigmentosa. A morphometric analysis. Arch Ophthalmol 1997;115:511–515.
- Walia S, Fishman GA, Edward DP, Lindeman M: Retinal nerve fiber layer defects in RP patients. Invest Ophthalmol Vis Sci 2007;48:4748–4752.
- Walia S, Fishman GA: Retinal nerve fiber layer analysis in RP patients using Fourier-domain OCT. Invest Ophthalmol Vis Sci 2008;49:3525–3528.
- Hood DC, Lin CE, Lazow MA: Thickness of receptor and post-receptor retinal layers in patients with retinitis pigmentosa measured with frequency-domain optical coherence tomography. Invest Ophthalmol Vis Sci 2009;50:2328–2336.
- Weinreb RN, Shakiba S, Zangwill L: Scanning laser polarimetry to measure the nerve fiber layer of normal and glaucomatous eyes. Am J Ophthalmol 1995;119:627–636.
- Reus NJ, Zhou Q, Lemij HG: Enhanced imaging algorithm for scanning laser polarimetry with variable corneal compensation. Invest Ophthalmol Vis Sci 2006;47:3870–3877.
- Costa-Cunha LV, Cunha LP, Malta RF, et al: Comparison of Fourier-domain and time-domain optical coherence tomography in the detection of band atrophy of the optic nerve. Am J Ophthalmol 2009;147:56–63.
- MenkeMN, Knecht P, Sturm V, et al: Reproducibility of nerve fiber layer thickness measurements using 3D Fourier-domain OCT. Invest Ophthalmol Vis Sci 2008;49:5386–5391.
- Oishi A, Otani M, Sasahara M, et al: Retinal nerve fiber layer thickness in patients with retinitis pigmentosa. Eye 2009;23:561–566.
-
Huang Q, Chowdhury V,Coroneo MT: Evaluation of patient suitability for a retinal prosthesis using structural and functional tests of inner retinal integrity. J Neural Eng 2009;6:035010.
External Resources
Article / Publication Details
Received: January 24, 2011
Accepted: February 02, 2012
Published online: October 12, 2012
Issue release date: December 2012
Number of Print Pages: 5
Number of Figures: 1
Number of Tables: 2
ISSN: 0030-3755 (Print)
eISSN: 1423-0267 (Online)
For additional information: https://www.karger.com/OPH
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
